newsfilter
← Latest News
GlobeNewswire·

INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA

  • INVO Fertility reported Q3 2026 total revenue of $2,222,656, a 26% increase from $1,757,094 in Q3 2025.
  • Consolidated clinic revenue rose 28% to $2,207,587, driven by organic growth at Wisconsin & Atlanta clinics alongside full-quarter contributions from acquired Indiana & Birmingham clinics.
  • Net loss narrowed to $2.1 million from $3.4 million in the prior-year quarter, while loss from operations improved to $1.5 million from $1.6 million.
  • Clinic-Level Adjusted EBITDA remained positive for the seventh consecutive quarter at $292,114, despite a $193,000 impact from the Birmingham acquisition transition.
  • Consolidated Adjusted EBITDA was $(1.0) million, compared to $(0.9) million in Q3 2025, reflecting public company operating costs.
  • Cash balances reached $3.7 million at September 30, 2026, representing approximately $3.10 per share.
  • The balance sheet strengthened with total assets increasing by $5.3 million to $25.5 million, while liabilities decreased by $5.5 million to $7.5 million.
  • Net equity grew to $18.0 million, or $15.09 per share, up from $7.2 million at year-end 2025.
  • Current liabilities fell to $4.5 million from $10.3 million at December 31, 2025, following debt repayments.
  • The company acquired the remaining 50% interest in its Birmingham clinic in June 2026 for $175,001 to enable full ownership operations.
  • As of November 13, 2026, the company had 1,192,860 common shares outstanding.
  • Management cited entry into the Progyny network by the Wisconsin clinic as a factor expanding patient access for growth.
Company
INVO Fertility, Inc.
Keywords
Nasdaq:IVF, INVO Fertility, Inc., INVO Fertility, INVO Centers, INVOcell, Fertility Treatment, Fertility Centers, Earnings